Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Часто задаваемые вопросы
В каком секторе работает Xenon Pharmaceuticals Inc (XENE)?
Xenon Pharmaceuticals Inc относится к сектору Здравоохранение.
Какова текущая цена акций Xenon Pharmaceuticals Inc (XENE)?
По последним данным, цена акций Xenon Pharmaceuticals Inc составляет 35,77 $, предыдущее закрытие — 35,34 $. За последнюю торговую сессию акции Xenon Pharmaceuticals Inc выросли на 0,43 $, что соответствует росту на 1,22%.
Выплачивает ли Xenon Pharmaceuticals Inc (XENE) дивиденды?
Нет, Xenon Pharmaceuticals Inc не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Xenon Pharmaceuticals Inc (XENE)?
У компании Xenon Pharmaceuticals Inc бета 0.627, что указывает на более низкую волатильность по сравнению с рынком в целом.
